168 related articles for article (PubMed ID: 26676883)
21. Identification of drug-regulated genes in osteosarcoma cells.
Fellenberg J; Dechant MJ; Ewerbeck V; Mau H
Int J Cancer; 2003 Jul; 105(5):636-43. PubMed ID: 12740912
[TBL] [Abstract][Full Text] [Related]
22. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
23. Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells.
Sun X; Wei Q; Cheng J; Bian Y; Tian C; Hu Y; Li H
Hum Cell; 2017 Jul; 30(3):216-225. PubMed ID: 28326487
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance.
Jia Y; Zhang W; Liu H; Peng L; Yang Z; Lou J
Cancer Chemother Pharmacol; 2012 Feb; 69(2):377-85. PubMed ID: 21833590
[TBL] [Abstract][Full Text] [Related]
25. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
26. miR-214 modulates cisplatin sensitivity of osteosarcoma cells through regulation of anaerobic glycolysis.
Song YD; Li DD; Guan Y; Wang YL; Zheng J
Cell Mol Biol (Noisy-le-grand); 2017 Sep; 63(9):75-79. PubMed ID: 28980925
[TBL] [Abstract][Full Text] [Related]
27. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Long X; Lin XJ
J Cell Biochem; 2019 Apr; 120(4):5652-5665. PubMed ID: 30387173
[TBL] [Abstract][Full Text] [Related]
28. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
He C; Sun Z; Hoffman RM; Yang Z; Jiang Y; Wang L; Hao Y
Anticancer Res; 2019 Apr; 39(4):1711-1718. PubMed ID: 30952710
[TBL] [Abstract][Full Text] [Related]
29. Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.
Collier CD; Wirtz EC; Knafler GJ; Morris WZ; Getty PJ; Greenfield EM
Clin Orthop Relat Res; 2018 Jul; 476(7):1400-1411. PubMed ID: 29481344
[TBL] [Abstract][Full Text] [Related]
30. Krüppel-Like Factor 4 Enhances Sensitivity of Cisplatin to Esophageal Squamous Cell Carcinoma (ESCC) Cells.
Chen C; Ma Z; Zhang H; Liu X; Yu Z
Med Sci Monit; 2017 Jul; 23():3353-3359. PubMed ID: 28694421
[TBL] [Abstract][Full Text] [Related]
31. GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy.
Kim M; Jung JY; Choi S; Lee H; Morales LD; Koh JT; Kim SH; Choi YD; Choi C; Slaga TJ; Kim WJ; Kim DJ
Autophagy; 2017 Jan; 13(1):149-168. PubMed ID: 27754745
[TBL] [Abstract][Full Text] [Related]
32. TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma.
Li C; Cai J; Ge F; Wang G
Int J Mol Med; 2018 Oct; 42(4):1799-1808. PubMed ID: 30015899
[TBL] [Abstract][Full Text] [Related]
33. HMGB1 promotes drug resistance in osteosarcoma.
Huang J; Ni J; Liu K; Yu Y; Xie M; Kang R; Vernon P; Cao L; Tang D
Cancer Res; 2012 Jan; 72(1):230-8. PubMed ID: 22102692
[TBL] [Abstract][Full Text] [Related]
34. Roles of microRNA-22 in Suppressing Proliferation and Promoting Sensitivity of Osteosarcoma Cells via Metadherin-mediated Autophagy.
Wang P; Zhao ZQ; Guo SB; Yang TY; Chang ZQ; Li DH; Zhao W; Wang YX; Sun C; Wang Y; Feng W
Orthop Surg; 2019 Apr; 11(2):285-293. PubMed ID: 30932352
[TBL] [Abstract][Full Text] [Related]
35. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
36. Targeting hedgehog-GLI-2 pathway in osteosarcoma.
Yang W; Liu X; Choy E; Mankin H; Hornicek FJ; Duan Z
J Orthop Res; 2013 Mar; 31(3):502-9. PubMed ID: 22968906
[TBL] [Abstract][Full Text] [Related]
37. Ca
Ohya S; Kajikuri J; Endo K; Kito H; Elboray EE; Suzuki T
Cancer Sci; 2021 Sep; 112(9):3769-3783. PubMed ID: 34181803
[TBL] [Abstract][Full Text] [Related]
38. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
Dieudonné FX; Marion A; Marie PJ; Modrowski D
J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
[TBL] [Abstract][Full Text] [Related]
39. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
[TBL] [Abstract][Full Text] [Related]
40. Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma.
Huang J; Liu K; Yu Y; Xie M; Kang R; Vernon P; Cao L; Tang D; Ni J
Autophagy; 2012 Feb; 8(2):275-7. PubMed ID: 22301993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
